Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer

Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer

US Patent 8481001 · Granted Jul 9, 2013

Estimated economic value: $4,294,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Humanised anti-n-truncated amyloid β monoclonal antibody2025
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorop2025
Humanised anti-IL17BR antibody2025
(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-2024
Resealable bag enclosure2023
Anti-transglutaminase 2 antibodies2023
Method of feeding web and reclosures to a form fill seal machine2022
(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-2022
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorop2021
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorop2021
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluoro2021
Drug combinations to treat multiple myeloma2021